Synthetic test data. This release was generated from a synthetic store to exercise the pipeline. Nothing in it is a report from a person.

Release

EXAMPLE-SYNTHETIC

Computed on 2026-12-31 from every report received to that date, under release specification v0.1 and schema 0.1-draft.

Reports committed: 1,500
Excluded: 0 (none) — list
Analysed: 1,500
Merkle root: cdba617d2c556c70a2fb1b1557ae6d62f2eb1e7e05bd0871092c6810efd207eb
over 1,500 leaves — leaf list
Files: release.json (hash of every file) · how we count reports
Witness: not yet witnessed

Read every figure with these in mind. The people who report here chose to; they are not a sample of anyone. They reported from memory, after the fact, knowing what they took and what they hoped for. Two vials sold under the same name can contain different things. Nothing here is a clinical trial, a rate, a comparison, or evidence that anything works or is safe. Where most people report no change, that is the most trustworthy number on the page — every bias above pushes the other way.

Counts by compound

Compounds appear in the fixed order of the schema, never ordered by any result. What is shown for each depends only on how many reports it has.

GLP-1 / incretin agonists — 227 reports
Compound	Reports	Shown
Retatrutide	43	count, route and source
Tirzepatide	36	count, route and source
Semaglutide	35	count, route and source
Cagrilintide	28	count, route and source
Mazdutide	30	count, route and source
Survodutide	33	count, route and source
Liraglutide	22	count, route and source

Growth hormone axis — 158 reports
Compound	Reports	Shown
CJC-1295 (no DAC) / ipamorelin blend	16	count, route and source
Ipamorelin	18	count, route and source
Tesamorelin	21	count, route and source
MK-677 (ibutamoren)	10	count, route and source
Somatropin (HGH)	12	count, route and source
CJC-1295 without DAC (Mod GRF 1-29)	12	count, route and source
Sermorelin	19	count, route and source
CJC-1295 with DAC	11	count, route and source
GHRP-6	14	count, route and source
GHRP-2 (pralmorelin)	17	count, route and source
Hexarelin	fewer than 10 reports — not enough to show	fewer than 10 reports

Tissue repair / healing — 333 reports
Compound	Reports	Shown
GHK-Cu	272	plus percentages and effect timing
BPC-157	11	count, route and source
TB-500	10	count, route and source
BPC-157 + TB-500 blend (Wolverine stack)	fewer than 10 reports — not enough to show	fewer than 10 reports
KPV	12	count, route and source
LL-37	11	count, route and source
ARA-290 (cibinetide)	10	count, route and source

Nootropic / mood / sleep — 232 reports
Compound	Reports	Shown
Oxytocin (intranasal)	62	all one-way tables
DSIP (delta sleep-inducing peptide)	54	all one-way tables
Semax	21	count, route and source
Selank	29	count, route and source
Cerebrolysin	16	count, route and source
Dihexa	19	count, route and source
P21 (P021)	20	count, route and source
Pinealon	11	count, route and source

Metabolic / longevity — 114 reports
Compound	Reports	Shown
AOD-9604	10	count, route and source
NAD+ (injectable)	13	count, route and source
MOTS-c	fewer than 10 reports — not enough to show	fewer than 10 reports
Epitalon	10	count, route and source
5-amino-1MQ	11	count, route and source
Glutathione (injectable)	14	count, route and source
Thymosin alpha-1	fewer than 10 reports — not enough to show	fewer than 10 reports
Tesofensine	fewer than 10 reports — not enough to show	fewer than 10 reports
SS-31 (elamipretide)	fewer than 10 reports — not enough to show	fewer than 10 reports
Humanin	11	count, route and source
SLU-PP-332	10	count, route and source
FOXO4-DRI	fewer than 10 reports — not enough to show	fewer than 10 reports

Sexual function / hormonal — 409 reports
Compound	Reports	Shown
PT-141 (bremelanotide)	137	plus outcome by goal
Melanotan II	89	all one-way tables
Kisspeptin-10	86	all one-way tables
Melanotan I (afamelanotide)	50	all one-way tables
Gonadorelin	47	count, route and source

Other (not listed): 27 reports. Counted, never broken out.

By compound

Retatrutide — 43 reports · count, route and source

Retatrutide — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	43
All	43

Retatrutide — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	6
Telehealth or clinic (compounded)	6
Domestic research-chemical vendor	10
Overseas vendor	13
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	43

Tirzepatide — 36 reports · count, route and source

Tirzepatide — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	23
Oral / sublingual / troche	13
All	36

Tirzepatide — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	7
Telehealth or clinic (compounded)	not shown
Domestic research-chemical vendor	10
Overseas vendor	7
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	36

Semaglutide — 35 reports · count, route and source

Semaglutide — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	26
Oral / sublingual / troche	9
All	35

Semaglutide — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	not shown
Telehealth or clinic (compounded)	8
Domestic research-chemical vendor	11
Overseas vendor	6
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	35

Cagrilintide — 28 reports · count, route and source

Cagrilintide — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	28
All	28

Cagrilintide — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	5
Telehealth or clinic (compounded)	not shown
Domestic research-chemical vendor	16
Overseas vendor	not shown
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	28

Mazdutide — 30 reports · count, route and source

Mazdutide — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	30
All	30

Mazdutide — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	not shown
Telehealth or clinic (compounded)	5
Domestic research-chemical vendor	11
Overseas vendor	7
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	30

Survodutide — 33 reports · count, route and source

Survodutide — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	33
All	33

Survodutide — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	5
Telehealth or clinic (compounded)	7
Domestic research-chemical vendor	9
Overseas vendor	not shown
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	33

Liraglutide — 22 reports · count, route and source

Liraglutide — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	22
All	22

Liraglutide — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	6
Telehealth or clinic (compounded)	not shown
Domestic research-chemical vendor	8
Overseas vendor	not shown
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	22

CJC-1295 (no DAC) / ipamorelin blend — 16 reports · count, route and source

CJC-1295 (no DAC) / ipamorelin blend — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	16
All	16

CJC-1295 (no DAC) / ipamorelin blend — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	not shown
Telehealth or clinic (compounded)	not shown
Domestic research-chemical vendor	5
Overseas vendor	5
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	16

Ipamorelin — 18 reports · count, route and source

Ipamorelin — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	18
All	18

Ipamorelin — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	not shown
Telehealth or clinic (compounded)	6
Domestic research-chemical vendor	not shown
Overseas vendor	not shown
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	18

Tesamorelin — 21 reports · count, route and source

Tesamorelin — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	21
All	21

Tesamorelin — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	not shown
Telehealth or clinic (compounded)	5
Domestic research-chemical vendor	10
Overseas vendor	not shown
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	21

MK-677 (ibutamoren) — 10 reports · count, route and source

MK-677 (ibutamoren) — route — the same numbers are in the table below

Answer	Reports
Oral / sublingual / troche	10
All	10

MK-677 (ibutamoren) — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	not shown
Telehealth or clinic (compounded)	not shown
Domestic research-chemical vendor	not shown
Overseas vendor	not shown
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	10

Somatropin (HGH) — 12 reports · count, route and source

Somatropin (HGH) — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	not shown
Intramuscular injection	not shown
All	12

Somatropin (HGH) — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	not shown
Telehealth or clinic (compounded)	5
Domestic research-chemical vendor	not shown
Overseas vendor	not shown
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	12

CJC-1295 without DAC (Mod GRF 1-29) — 12 reports · count, route and source

CJC-1295 without DAC (Mod GRF 1-29) — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	12
All	12

CJC-1295 without DAC (Mod GRF 1-29) — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	not shown
Telehealth or clinic (compounded)	not shown
Domestic research-chemical vendor	not shown
Overseas vendor	not shown
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	12

Sermorelin — 19 reports · count, route and source

Sermorelin — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	19
All	19

Sermorelin — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	6
Telehealth or clinic (compounded)	not shown
Domestic research-chemical vendor	not shown
Overseas vendor	6
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	19

CJC-1295 with DAC — 11 reports · count, route and source

CJC-1295 with DAC — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	11
All	11

CJC-1295 with DAC — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	not shown
Telehealth or clinic (compounded)	not shown
Domestic research-chemical vendor	not shown
Overseas vendor	not shown
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	11

GHRP-6 — 14 reports · count, route and source

GHRP-6 — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	14
All	14

GHRP-6 — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	not shown
Telehealth or clinic (compounded)	not shown
Domestic research-chemical vendor	not shown
Overseas vendor	not shown
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	14

GHRP-2 (pralmorelin) — 17 reports · count, route and source

GHRP-2 (pralmorelin) — route — the same numbers are in the table below

Answer	Reports
Subcutaneous injection	17
All	17

GHRP-2 (pralmorelin) — source channel — the same numbers are in the table below

Answer	Reports
Retail pharmacy (brand product, prescription)	not shown
Compounding pharmacy	5
Telehealth or clinic (compounded)	not shown
Domestic research-chemical vendor	6
Overseas vendor	not shown
From another person	not shown
Don't know	not shown
Other (not listed)	not shown
All	17

GHK-Cu — 272 reports · plus percentages and effect timing

GHK-Cu — route — the same numbers are in the table below

Answer	Percent (95% interval) · reports
Topical / transdermal	70.6% (65–76) · 192
Subcutaneous injection	29.4% (24–35) · 80
All	272

GHK-Cu — source channel — the same numbers are in the table below

Answer	Percent (95% interval) · reports
Retail pharmacy (brand product, prescription)	4.8% (3–8) · 13
Compounding pharmacy	14.0% (10–19) · 38
Telehealth or clinic (compounded)	19.9% (16–25) · 54
Domestic research-chemical vendor	28.7% (24–34) · 78
Overseas vendor	22.1% (18–27) · 60
From another person	5.1% (3–9) · 14
Don't know	3.7% (2–7) · 10
Other (not listed)	1.8% (1–4) · 5
All	272

GHK-Cu — what people took it for — the same numbers are in the table below

Answer	Percent (95% interval) · reports
Skin appearance / fine lines / anti-aging look	37.1% (32–43) · 101
Hair regrowth or thicker hair	16.2% (12–21) · 44
Healing wounds, scars, acne marks or stretch marks	14.7% (11–19) · 40
More even skin tone	10.7% (8–15) · 29
Healing a tendon, ligament, muscle or joint injury	11.4% (8–16) · 31
General longevity / anti-aging	5.1% (3–9) · 14
Other (not listed)	4.8% (3–8) · 13
All	272

GHK-Cu — starting dose — the same numbers are in the table below

Answer	Percent (95% interval) · reports
Topical only (no injection)	25.4% (21–31) · 69
Under 1 mg per day injected	31.6% (26–37) · 86
1 to 2 mg per day injected	22.1% (18–27) · 60
2 to 4 mg per day injected	12.9% (9–17) · 35
Over 4 mg per day injected	8.1% (5–12) · 22
All	272

GHK-Cu — current or final dose — the same numbers are in the table below

Answer	Percent (95% interval) · reports
Topical only (no injection)	19.1% (15–24) · 52
Under 1 mg per day injected	29.8% (25–36) · 81
1 to 2 mg per day injected	22.4% (18–28) · 61
2 to 4 mg per day injected	16.9% (13–22) · 46
Over 4 mg per day injected	11.8% (9–16) · 32
All	272

GHK-Cu — frequency — the same numbers are in the table below

Answer	Percent (95% interval) · reports
Once a day	39.7% (34–46) · 108
5 days on / 2 days off	20.2% (16–25) · 55
2–3 times a week	12.9% (9–17) · 35
About once a week	9.6% (7–14) · 26
More than once a day	7.4% (5–11) · 20
In cycles (weeks on, weeks off)	6.2% (4–10) · 17
Other (not listed)	4.0% (2–7) · 11
All	272

GHK-Cu — duration — the same numbers are in the table below

Answer	Percent (95% interval) · reports
Under 2 weeks	9.9% (7–14) · 27
2 to 4 weeks	21.3% (17–27) · 58
1 to 3 months	32.4% (27–38) · 88
3 to 6 months	19.1% (15–24) · 52
6 to 12 months	10.3% (7–15) · 28
Over 12 months	7.0% (5–11) · 19
All	272

GHK-Cu — independent purity testing — the same numbers are in the table below

Answer	Percent (95% interval) · reports
No, did not test	70.2% (65–75) · 191
Yes — result matched the label	17.6% (14–23) · 48
Yes — result did not match the label	2.9% (2–6) · 8
Yes — unsure how to read the result	4.0% (2–7) · 11
Don't know	5.1% (3–9) · 14
All	272

GHK-Cu — outcome by goal — the same numbers are in the table below

	No change	Slight improvement	Moderate improvement	Large improvement	n
Skin appearance / fine lines / anti-aging look	36.6% (28–46) · 37	26.7% (19–36) · 27	29.7% (22–39) · 30	6.9% (3–14) · 7	101
Hair regrowth or thicker hair	11	14	10	9	44
Healing wounds, scars, acne marks or stretch marks	16	14	not shown	not shown	40
More even skin tone	13	6	not shown	not shown	29
Healing a tendon, ligament, muscle or joint injury	13	8	not shown	not shown	31
General longevity / anti-aging	fewer than 20 reports

GHK-Cu — side effects reported — the same numbers are in the table below

Answer	Percent (95% interval) · reports
No side effects reported	49.6% (44–56) · 135
Headache	5.5% (3–9) · 15
Nausea	9.2% (6–13) · 25
Vomiting	4.4% (3–8) · 12
Dizziness or lightheadedness	3.3% (2–6) · 9
Fatigue / low energy	5.5% (3–9) · 15
Trouble sleeping	4.4% (3–8) · 12
Vivid dreams	4.8% (3–8) · 13
Flushing or feeling warm	6.2% (4–10) · 17
Anxiety, restlessness or feeling wired	4.8% (3–8) · 13
Low mood or irritability	5.1% (3–9) · 14
Appetite change	5.9% (4–9) · 16
Injection-site reaction (redness, itching, lump, bruising)	1.8% (1–4) · 5
Nasal irritation, burning or sneezing	not shown
Effect faded with repeated use	2.2% (1–5) · 6
No noticeable effect at all	3.3% (2–6) · 9
Blue-green staining or residue on skin	2.6% (1–5) · 7
Skin irritation, rash, hives or breakouts	6.6% (4–10) · 18
Hair shedding	4.0% (2–7) · 11
All	272

GHK-Cu — nausea: when it started — the same numbers are in the table below

GHK-Cu — nausea: after stopping — the same numbers are in the table below

GHK-Cu — still taking, stopped, or finished — the same numbers are in the table below

GHK-Cu — main reason for stopping — the same numbers are in the table below

BPC-157 — 11 reports · count, route and source

BPC-157 — route — the same numbers are in the table below

BPC-157 — source channel — the same numbers are in the table below

TB-500 — 10 reports · count, route and source

TB-500 — route — the same numbers are in the table below

TB-500 — source channel — the same numbers are in the table below

KPV — 12 reports · count, route and source

KPV — route — the same numbers are in the table below

KPV — source channel — the same numbers are in the table below

LL-37 — 11 reports · count, route and source

LL-37 — route — the same numbers are in the table below

LL-37 — source channel — the same numbers are in the table below

ARA-290 (cibinetide) — 10 reports · count, route and source

ARA-290 (cibinetide) — route — the same numbers are in the table below

ARA-290 (cibinetide) — source channel — the same numbers are in the table below

Oxytocin (intranasal) — 62 reports · all one-way tables

Oxytocin (intranasal) — route — the same numbers are in the table below

Oxytocin (intranasal) — source channel — the same numbers are in the table below

Oxytocin (intranasal) — what people took it for — the same numbers are in the table below

Oxytocin (intranasal) — starting dose — the same numbers are in the table below

Oxytocin (intranasal) — current or final dose — the same numbers are in the table below

Oxytocin (intranasal) — frequency — the same numbers are in the table below

Oxytocin (intranasal) — duration — the same numbers are in the table below

Oxytocin (intranasal) — independent purity testing — the same numbers are in the table below

Oxytocin (intranasal) — side effects reported — the same numbers are in the table below

Oxytocin (intranasal) — still taking, stopped, or finished — the same numbers are in the table below

Oxytocin (intranasal) — main reason for stopping — the same numbers are in the table below

DSIP (delta sleep-inducing peptide) — 54 reports · all one-way tables

DSIP (delta sleep-inducing peptide) — route — the same numbers are in the table below

DSIP (delta sleep-inducing peptide) — source channel — the same numbers are in the table below

DSIP (delta sleep-inducing peptide) — what people took it for — the same numbers are in the table below

DSIP (delta sleep-inducing peptide) — starting dose — the same numbers are in the table below

DSIP (delta sleep-inducing peptide) — current or final dose — the same numbers are in the table below

DSIP (delta sleep-inducing peptide) — frequency — the same numbers are in the table below

DSIP (delta sleep-inducing peptide) — duration — the same numbers are in the table below

DSIP (delta sleep-inducing peptide) — independent purity testing — the same numbers are in the table below

DSIP (delta sleep-inducing peptide) — side effects reported — the same numbers are in the table below

DSIP (delta sleep-inducing peptide) — still taking, stopped, or finished — the same numbers are in the table below

DSIP (delta sleep-inducing peptide) — main reason for stopping — the same numbers are in the table below

Semax — 21 reports · count, route and source

Semax — route — the same numbers are in the table below

Semax — source channel — the same numbers are in the table below

Selank — 29 reports · count, route and source

Selank — route — the same numbers are in the table below

Selank — source channel — the same numbers are in the table below

Cerebrolysin — 16 reports · count, route and source

Cerebrolysin — route — the same numbers are in the table below

Cerebrolysin — source channel — the same numbers are in the table below

Dihexa — 19 reports · count, route and source

Dihexa — route — the same numbers are in the table below

Dihexa — source channel — the same numbers are in the table below

P21 (P021) — 20 reports · count, route and source

P21 (P021) — route — the same numbers are in the table below

P21 (P021) — source channel — the same numbers are in the table below

Pinealon — 11 reports · count, route and source

Pinealon — route — the same numbers are in the table below

Pinealon — source channel — the same numbers are in the table below

AOD-9604 — 10 reports · count, route and source

AOD-9604 — route — the same numbers are in the table below

AOD-9604 — source channel — the same numbers are in the table below

NAD+ (injectable) — 13 reports · count, route and source

NAD+ (injectable) — route — the same numbers are in the table below

NAD+ (injectable) — source channel — the same numbers are in the table below

Epitalon — 10 reports · count, route and source

Epitalon — route — the same numbers are in the table below

Epitalon — source channel — the same numbers are in the table below

5-amino-1MQ — 11 reports · count, route and source

5-amino-1MQ — route — the same numbers are in the table below

5-amino-1MQ — source channel — the same numbers are in the table below

Glutathione (injectable) — 14 reports · count, route and source

Glutathione (injectable) — route — the same numbers are in the table below

Glutathione (injectable) — source channel — the same numbers are in the table below

Humanin — 11 reports · count, route and source

Humanin — route — the same numbers are in the table below

Humanin — source channel — the same numbers are in the table below

SLU-PP-332 — 10 reports · count, route and source

SLU-PP-332 — route — the same numbers are in the table below

SLU-PP-332 — source channel — the same numbers are in the table below

PT-141 (bremelanotide) — 137 reports · plus outcome by goal

PT-141 (bremelanotide) — route — the same numbers are in the table below

PT-141 (bremelanotide) — source channel — the same numbers are in the table below

PT-141 (bremelanotide) — what people took it for — the same numbers are in the table below

PT-141 (bremelanotide) — starting dose — the same numbers are in the table below

PT-141 (bremelanotide) — current or final dose — the same numbers are in the table below

PT-141 (bremelanotide) — frequency — the same numbers are in the table below

PT-141 (bremelanotide) — duration — the same numbers are in the table below

PT-141 (bremelanotide) — independent purity testing — the same numbers are in the table below

PT-141 (bremelanotide) — outcome by goal — the same numbers are in the table below

PT-141 (bremelanotide) — side effects reported — the same numbers are in the table below

PT-141 (bremelanotide) — still taking, stopped, or finished — the same numbers are in the table below

PT-141 (bremelanotide) — main reason for stopping — the same numbers are in the table below

Melanotan II — 89 reports · all one-way tables

Melanotan II — route — the same numbers are in the table below

Melanotan II — source channel — the same numbers are in the table below

Melanotan II — what people took it for — the same numbers are in the table below

Melanotan II — starting dose — the same numbers are in the table below

Melanotan II — current or final dose — the same numbers are in the table below

Melanotan II — frequency — the same numbers are in the table below

Melanotan II — duration — the same numbers are in the table below

Melanotan II — independent purity testing — the same numbers are in the table below

Melanotan II — side effects reported — the same numbers are in the table below

Melanotan II — still taking, stopped, or finished — the same numbers are in the table below

Melanotan II — main reason for stopping — the same numbers are in the table below

Kisspeptin-10 — 86 reports · all one-way tables

Kisspeptin-10 — route — the same numbers are in the table below

Kisspeptin-10 — source channel — the same numbers are in the table below

Kisspeptin-10 — what people took it for — the same numbers are in the table below

Kisspeptin-10 — starting dose — the same numbers are in the table below

Kisspeptin-10 — current or final dose — the same numbers are in the table below

Kisspeptin-10 — frequency — the same numbers are in the table below

Kisspeptin-10 — duration — the same numbers are in the table below

Kisspeptin-10 — independent purity testing — the same numbers are in the table below

Kisspeptin-10 — side effects reported — the same numbers are in the table below

Kisspeptin-10 — still taking, stopped, or finished — the same numbers are in the table below

Kisspeptin-10 — main reason for stopping — the same numbers are in the table below

Melanotan I (afamelanotide) — 50 reports · all one-way tables

Melanotan I (afamelanotide) — route — the same numbers are in the table below

Melanotan I (afamelanotide) — source channel — the same numbers are in the table below

Melanotan I (afamelanotide) — what people took it for — the same numbers are in the table below

Melanotan I (afamelanotide) — starting dose — the same numbers are in the table below

Melanotan I (afamelanotide) — current or final dose — the same numbers are in the table below

Melanotan I (afamelanotide) — frequency — the same numbers are in the table below

Melanotan I (afamelanotide) — duration — the same numbers are in the table below

Melanotan I (afamelanotide) — independent purity testing — the same numbers are in the table below

Melanotan I (afamelanotide) — side effects reported — the same numbers are in the table below

Melanotan I (afamelanotide) — still taking, stopped, or finished — the same numbers are in the table below

Gonadorelin — 47 reports · count, route and source

Gonadorelin — route — the same numbers are in the table below

Gonadorelin — source channel — the same numbers are in the table below

By class

GLP-1 / incretin agonists — 227 reports across 7 compounds

GLP-1 / incretin agonists — route — the same numbers are in the table below

GLP-1 / incretin agonists — source channel — the same numbers are in the table below

GLP-1 / incretin agonists — what people took it for — the same numbers are in the table below

GLP-1 / incretin agonists — frequency — the same numbers are in the table below

GLP-1 / incretin agonists — duration — the same numbers are in the table below

GLP-1 / incretin agonists — independent purity testing — the same numbers are in the table below

GLP-1 / incretin agonists — outcome by goal — the same numbers are in the table below

GLP-1 / incretin agonists — side effects reported — the same numbers are in the table below

GLP-1 / incretin agonists — still taking, stopped, or finished — the same numbers are in the table below

GLP-1 / incretin agonists — main reason for stopping — the same numbers are in the table below

Growth hormone axis — 158 reports across 11 compounds

Growth hormone axis — route — the same numbers are in the table below

Growth hormone axis — source channel — the same numbers are in the table below

Growth hormone axis — what people took it for — the same numbers are in the table below

Growth hormone axis — frequency — the same numbers are in the table below

Growth hormone axis — duration — the same numbers are in the table below

Growth hormone axis — independent purity testing — the same numbers are in the table below

Growth hormone axis — outcome by goal — the same numbers are in the table below

Growth hormone axis — side effects reported — the same numbers are in the table below

Growth hormone axis — still taking, stopped, or finished — the same numbers are in the table below

Growth hormone axis — main reason for stopping — the same numbers are in the table below

Tissue repair / healing — 333 reports across 7 compounds

Tissue repair / healing — route — the same numbers are in the table below

Tissue repair / healing — source channel — the same numbers are in the table below

Tissue repair / healing — what people took it for — the same numbers are in the table below

Tissue repair / healing — frequency — the same numbers are in the table below

Tissue repair / healing — duration — the same numbers are in the table below

Tissue repair / healing — independent purity testing — the same numbers are in the table below

Tissue repair / healing — outcome by goal — the same numbers are in the table below

Tissue repair / healing — side effects reported — the same numbers are in the table below

Tissue repair / healing — headache: when it started — the same numbers are in the table below

Tissue repair / healing — headache: after stopping — the same numbers are in the table below

Tissue repair / healing — nausea: when it started — the same numbers are in the table below

Tissue repair / healing — nausea: after stopping — the same numbers are in the table below

Tissue repair / healing — flushing or feeling warm: when it started — the same numbers are in the table below

Tissue repair / healing — flushing or feeling warm: after stopping — the same numbers are in the table below

Tissue repair / healing — still taking, stopped, or finished — the same numbers are in the table below

Tissue repair / healing — main reason for stopping — the same numbers are in the table below

Nootropic / mood / sleep — 232 reports across 8 compounds

Nootropic / mood / sleep — route — the same numbers are in the table below

Nootropic / mood / sleep — source channel — the same numbers are in the table below

Nootropic / mood / sleep — what people took it for — the same numbers are in the table below

Nootropic / mood / sleep — frequency — the same numbers are in the table below

Nootropic / mood / sleep — duration — the same numbers are in the table below

Nootropic / mood / sleep — independent purity testing — the same numbers are in the table below

Nootropic / mood / sleep — outcome by goal — the same numbers are in the table below

Nootropic / mood / sleep — side effects reported — the same numbers are in the table below

Nootropic / mood / sleep — still taking, stopped, or finished — the same numbers are in the table below

Nootropic / mood / sleep — main reason for stopping — the same numbers are in the table below

Metabolic / longevity — 114 reports across 12 compounds

Metabolic / longevity — route — the same numbers are in the table below

Metabolic / longevity — source channel — the same numbers are in the table below

Metabolic / longevity — what people took it for — the same numbers are in the table below

Metabolic / longevity — frequency — the same numbers are in the table below

Metabolic / longevity — duration — the same numbers are in the table below

Metabolic / longevity — independent purity testing — the same numbers are in the table below

Metabolic / longevity — outcome by goal — the same numbers are in the table below

Metabolic / longevity — side effects reported — the same numbers are in the table below

Metabolic / longevity — still taking, stopped, or finished — the same numbers are in the table below

Metabolic / longevity — main reason for stopping — the same numbers are in the table below

Sexual function / hormonal — 409 reports across 5 compounds

Sexual function / hormonal — route — the same numbers are in the table below

Sexual function / hormonal — source channel — the same numbers are in the table below

Sexual function / hormonal — what people took it for — the same numbers are in the table below

Sexual function / hormonal — frequency — the same numbers are in the table below

Sexual function / hormonal — duration — the same numbers are in the table below

Sexual function / hormonal — independent purity testing — the same numbers are in the table below

Sexual function / hormonal — outcome by goal — the same numbers are in the table below

Sexual function / hormonal — side effects reported — the same numbers are in the table below

Sexual function / hormonal — headache: when it started — the same numbers are in the table below

Sexual function / hormonal — headache: after stopping — the same numbers are in the table below

Sexual function / hormonal — nausea: when it started — the same numbers are in the table below

Sexual function / hormonal — nausea: after stopping — the same numbers are in the table below

Sexual function / hormonal — vomiting: when it started — the same numbers are in the table below

Sexual function / hormonal — vomiting: after stopping — the same numbers are in the table below

Sexual function / hormonal — dizziness or lightheadedness: when it started — the same numbers are in the table below

Sexual function / hormonal — dizziness or lightheadedness: after stopping — the same numbers are in the table below

Sexual function / hormonal — trouble sleeping: when it started — the same numbers are in the table below

Sexual function / hormonal — trouble sleeping: after stopping — the same numbers are in the table below

Sexual function / hormonal — flushing or feeling warm: when it started — the same numbers are in the table below

Sexual function / hormonal — flushing or feeling warm: after stopping — the same numbers are in the table below

Sexual function / hormonal — low mood or irritability: when it started — the same numbers are in the table below

Sexual function / hormonal — low mood or irritability: after stopping — the same numbers are in the table below

Sexual function / hormonal — appetite change: when it started — the same numbers are in the table below

Sexual function / hormonal — appetite change: after stopping — the same numbers are in the table below

Sexual function / hormonal — injection-site reaction (redness, itching, lump, bruising): when it started — the same numbers are in the table below

Sexual function / hormonal — injection-site reaction (redness, itching, lump, bruising): after stopping — the same numbers are in the table below

Sexual function / hormonal — effect faded with repeated use: when it started — the same numbers are in the table below

Sexual function / hormonal — effect faded with repeated use: after stopping — the same numbers are in the table below

Sexual function / hormonal — still taking, stopped, or finished — the same numbers are in the table below

Sexual function / hormonal — main reason for stopping — the same numbers are in the table below

All reports

Who contributed — age — the same numbers are in the table below

Who contributed — sex — the same numbers are in the table below

Integrity log

Before each release, the coordinated-submission detector (public code: tools/detect.py) flags reports that contradict themselves and unusual bursts, such as many reports about one compound arriving on one day. Flagged reports stay in the committed log but are left out of every table above.

No coordinated-submission pattern was identified in this period.

Reason	This period	All time
malformed	0	0
implausible	0	0
duplicate-pattern	0	0
coordinated	0	0
test	0	0

Flagged reports are listed by log position and reason in the exclusion list.

Uniqueness of the store

How distinctive a single row in the private store is on each set of fields an outsider might know. This is a property of data that is never published; it is reported so the de-identification analysis in the schema can be checked against real data.

Fields known	Rows unique	Rows in cells under 5	Median cell
narrow (compound, age_band, sex, goals, start_dose, source_channel, duration)	98.5%	100%	1
plausible-post (compound, age_band, sex, goals, start_dose)	76.7%	97.8%	1
plausible-post-no-dose (compound, age_band, sex, goals)	49.9%	85%	2
demographics-only (compound, age_band, sex)	21.3%	54.5%	4
broad (compound, age_band, sex, goals, start_dose, current_dose, source_channel, duration, purity_tested, status, stop_reason, adverse_effects, outcomes)	100%	100%	1

Answer	Percent (95% interval) · reports
Still taking it	38.6% (33–45) · 105
Finished a planned course	16.5% (13–21) · 45
Stopped before I planned to	44.9% (39–51) · 122
All	272

Answer	Percent (95% interval) · reports
Got what I wanted from it	25.4% (19–34) · 31
It wasn't doing anything	33.6% (26–42) · 41
Side effects	7.4% (4–13) · 9
Cost	9.8% (6–16) · 12
Couldn't get more	9.8% (6–16) · 12
Worried about safety	7.4% (4–13) · 9
Other (not listed)	6.6% (3–12) · 8
All	122

Answer	Reports
Nasal spray / drops	32
Oral / sublingual / troche	18
Subcutaneous injection	12
All	62

Answer	Reports
Feeling calmer or more at ease socially	20
Closer bonding or intimacy with a partner	18
More intense arousal or orgasm	13
Better mood / lifting depression	not shown
Less anxiety or stress	not shown
Deeper, more restorative sleep	not shown
Other (not listed)	not shown
All	62

Answer	Reports
Under 10 IU per dose	13
10 to under 20 IU per dose	17
20 to under 30 IU per dose	20
30 to 50 IU per dose	6
Over 50 IU per dose	6
All	62

Answer	Reports
As needed / on demand	25
Once a day	11
More than once a day	7
2–3 times a week	9
In cycles (weeks on, weeks off)	5
Other (not listed)	5
All	62

Answer	Reports
Falling asleep faster	21
Deeper, more restorative sleep	17
More daily energy, less fatigue	9
Less anxiety or stress	not shown
Other (not listed)	not shown
All	54

Answer	Reports
Under 100 mcg per dose	15
100 to under 200 mcg per dose	19
200 to under 400 mcg per dose	12
400 mcg to 1 mg per dose	not shown
Over 1 mg per dose	not shown
All	54

Answer	Reports
Stronger sexual desire / libido	59
Firmer or more reliable erections	30
Add-on when ED medication is not enough	24
More intense arousal or orgasm	15
Other (not listed)	9
All	137

Answer	Reports
Under 0.5 mg per dose	25
0.5 to under 1 mg per dose	48
1 to under 1.5 mg per dose	36
1.5 to 2 mg per dose	17
Over 2 mg per dose	11
All	137

Answer	Reports
Darker tan with less sun exposure	37
Tanning without burning / sun sensitivity	20
Stronger sexual desire / libido	14
Appetite control / quieting food noise	not shown
More even skin tone	8
Other (not listed)	not shown
All	89

Answer	Reports
Under 100 mcg per dose	32
100 to under 250 mcg per dose	28
250 to under 500 mcg per dose	12
500 mcg to 1 mg per dose	9
Over 1 mg per dose	8
All	89

Answer	Reports
Once a day	39
Every other day	17
2–3 times a week	16
About once a week	11
In cycles (weeks on, weeks off)	not shown
Other (not listed)	not shown
All	89

Answer	Reports
Higher natural testosterone	30
Stronger sexual desire / libido	16
Restoring hormone function after a cycle or TRT	19
Fertility	10
Better mood / lifting depression	not shown
Other (not listed)	not shown
All	86

Answer	Reports
Under 50 mcg per dose	16
50 to under 100 mcg per dose	29
100 to under 250 mcg per dose	19
250 to 500 mcg per dose	11
Over 500 mcg per dose	11
All	86

Answer	Reports
Under 0.5 mg per dose	10
0.5 to under 1 mg per dose	20
1 to 2 mg per dose	10
Over 2 mg per dose	10
All	50

Answer	Percent (95% interval) · reports
Subcutaneous injection	90.3% (86–94) · 205
Oral / sublingual / troche	9.7% (7–14) · 22
All	227

Answer	Percent (95% interval) · reports
Retail pharmacy (brand product, prescription)	5.7% (3–10) · 13
Compounding pharmacy	15.9% (12–21) · 36
Telehealth or clinic (compounded)	15.4% (11–21) · 35
Domestic research-chemical vendor	33.0% (27–39) · 75
Overseas vendor	18.5% (14–24) · 42
From another person	6.2% (4–10) · 14
Don't know	not shown
Other (not listed)	not shown
All	227

Answer	Percent (95% interval) · reports
Fat loss / weight loss	37.0% (31–44) · 84
Breaking a weight-loss plateau	9.7% (7–14) · 22
Losing fat while keeping or building muscle	4.0% (2–7) · 9
Appetite control / quieting food noise	9.7% (7–14) · 22
Cutting alcohol, nicotine or other cravings	5.3% (3–9) · 12
More endurance / exercise capacity	2.6% (1–6) · 6
Blood sugar / insulin resistance / A1c	7.5% (5–12) · 17
Joint pain or stiffness	not shown
PCOS-related weight or insulin issues	not shown
Maintaining weight after a prior loss (low-dose / microdose)	not shown
Heart or kidney protection	not shown
Adding to a GLP-1 for extra effect	4.8% (3–9) · 11
Reducing liver fat	7.9% (5–12) · 18
Alternative to weekly GLP-1 injections (oral / daily / cheaper)	not shown
Other (not listed)	7.0% (4–11) · 16
All	227

Answer	Percent (95% interval) · reports
About once a week	39.2% (33–46) · 89
More than once a day	23.8% (19–30) · 54
Less than weekly	8.8% (6–13) · 20
Once a day	10.1% (7–15) · 23
In cycles (weeks on, weeks off)	10.6% (7–15) · 24
Other (not listed)	7.5% (5–12) · 17
All	227

Answer	Percent (95% interval) · reports
Under 2 weeks	12.8% (9–18) · 29
2 to 4 weeks	18.5% (14–24) · 42
1 to 3 months	28.2% (23–34) · 64
3 to 6 months	23.8% (19–30) · 54
6 to 12 months	9.7% (7–14) · 22
Over 12 months	7.0% (4–11) · 16
All	227

Answer	Percent (95% interval) · reports
No, did not test	70.5% (64–76) · 160
Yes — result matched the label	11.9% (8–17) · 27
Yes — result did not match the label	6.2% (4–10) · 14
Yes — unsure how to read the result	5.7% (3–10) · 13
Don't know	5.7% (3–10) · 13
All	227

Answer	Percent (95% interval) · reports
No side effects reported	49.3% (43–56) · 112
Headache	3.1% (2–6) · 7
Nausea	5.3% (3–9) · 12
Vomiting	4.4% (2–8) · 10
Dizziness or lightheadedness	3.5% (2–7) · 8
Fatigue / low energy	4.8% (3–9) · 11
Trouble sleeping	2.2% (1–5) · 5
Vivid dreams	4.8% (3–9) · 11
Flushing or feeling warm	3.1% (2–6) · 7
Anxiety, restlessness or feeling wired	not shown
Low mood or irritability	4.4% (2–8) · 10
Appetite change	2.2% (1–5) · 5
Injection-site reaction (redness, itching, lump, bruising)	5.3% (3–9) · 12
Nasal irritation, burning or sneezing	not shown
Effect faded with repeated use	3.5% (2–7) · 8
No noticeable effect at all	4.0% (2–7) · 9
Constipation	not shown
Diarrhea or loose stools	5.3% (3–9) · 12
Acid reflux, bloating, burping or sulfur burps	4.8% (3–9) · 11
Racing heart, palpitations or higher resting heart rate	3.1% (2–6) · 7
Skin tingling, burning or sunburn-like sensitivity	not shown
Intense hunger or rebound cravings	not shown
Hair shedding	2.2% (1–5) · 5
Muscle loss or weakness	not shown
Next-day grogginess or hangover feeling	not shown
Low blood sugar episodes (shaky, sweaty, weak)	not shown
Gallbladder pain / gallstones	not shown
Facial volume loss or loose skin	not shown
Stomach pain or cramping	not shown
Getting full very fast / eating too little	not shown
All	227

Answer	Percent (95% interval) · reports
Still taking it	41.9% (36–48) · 95
Finished a planned course	11.5% (8–16) · 26
Stopped before I planned to	46.7% (40–53) · 106
All	227

Answer	Percent (95% interval) · reports
Got what I wanted from it	30.2% (22–40) · 32
It wasn't doing anything	29.2% (21–39) · 31
Side effects	8.5% (5–15) · 9
Cost	12.3% (7–20) · 13
Couldn't get more	5.7% (3–12) · 6
Worried about safety	6.6% (3–13) · 7
Other (not listed)	7.5% (4–14) · 8
All	106

Answer	Percent (95% interval) · reports
Topical / transdermal	58.6% (53–64) · 195
Subcutaneous injection	33.6% (29–39) · 112
Oral / sublingual / troche	4.2% (3–7) · 14
Nasal spray / drops	not shown
Intramuscular injection	not shown
All	333

Answer	Percent (95% interval) · reports
Retail pharmacy (brand product, prescription)	4.8% (3–8) · 16
Compounding pharmacy	16.8% (13–21) · 56
Telehealth or clinic (compounded)	18.3% (15–23) · 61
Domestic research-chemical vendor	28.5% (24–34) · 95
Overseas vendor	20.1% (16–25) · 67
From another person	5.1% (3–8) · 17
Don't know	4.2% (3–7) · 14
Other (not listed)	2.1% (1–4) · 7
All	333

Answer	Percent (95% interval) · reports
Skin appearance / fine lines / anti-aging look	30.3% (26–36) · 101
Hair regrowth or thicker hair	13.5% (10–18) · 45
Healing wounds, scars, acne marks or stretch marks	12.9% (10–17) · 43
More even skin tone	8.7% (6–12) · 29
Healing a tendon, ligament, muscle or joint injury	12.9% (10–17) · 43
General longevity / anti-aging	4.2% (3–7) · 14
Joint pain or stiffness	not shown
Gut issues (IBS, ulcers, leaky gut, inflammation)	2.1% (1–4) · 7
Recovery after surgery	not shown
Faster recovery from training	not shown
Recovery after concussion, head injury or stroke	not shown
An old or chronic injury that never fully healed	1.5% (1–4) · 5
Flexibility, mobility or stiffness	not shown
Skin condition (eczema, psoriasis, rosacea, acne)	not shown
Allergies, histamine or mast-cell issues	not shown
Autoimmune flares or body-wide inflammation	not shown
Sinus or respiratory issues	not shown
Chronic or stealth infection (Lyme, mold, biofilm)	not shown
Immune support / fewer infections	not shown
Gut infection or dysbiosis (SIBO, candida)	not shown
Long COVID or chronic fatigue symptoms	not shown
Nerve pain or neuropathy	1.5% (1–4) · 5
Other (not listed)	4.2% (3–7) · 14
All	333

Answer	Percent (95% interval) · reports
Once a day	38.4% (33–44) · 128
5 days on / 2 days off	16.5% (13–21) · 55
2–3 times a week	10.5% (8–14) · 35
About once a week	9.0% (6–13) · 30
More than once a day	9.6% (7–13) · 32
In cycles (weeks on, weeks off)	6.9% (5–10) · 23
Every other day	not shown
As needed / on demand	not shown
Other (not listed)	6.3% (4–9) · 21
All	333

Answer	Percent (95% interval) · reports
Under 2 weeks	10.8% (8–15) · 36
2 to 4 weeks	21.3% (17–26) · 71
1 to 3 months	31.2% (27–36) · 104
3 to 6 months	19.2% (15–24) · 64
6 to 12 months	9.6% (7–13) · 32
Over 12 months	7.8% (5–11) · 26
All	333